Payment overview · 2025
General Payments
$170.41
8 reported records · 4 companies
Healthcare provider profile · identity verified
Leann C Davidson, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · CHIPLEY, FL · NPI 1407140478
Verified facts
What the public records show
CMS Open Payments records show Leann C Davidson, ARNP received $170.41 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 71.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.61 | 71.4% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.33 | 10.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $15.30 | 9.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.17 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $170.41 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.24 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 370 | 85 |
| Lisinopril | Lisinopril | 294 | 65 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 269 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 259 | 49 |
| Tramadol Hcl | Tramadol Hcl | 244 | 46 |
| Omeprazole | Omeprazole | 223 | 51 |
| Furosemide | Furosemide | 199 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 40 |
| Carvedilol | Carvedilol | 183 | 37 |
| Gabapentin | Gabapentin | 181 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 47 |
| Montelukast Sodium | Montelukast Sodium | 175 | 37 |
| Simvastatin | Simvastatin | 168 | 36 |
| Meloxicam | Meloxicam | 161 | 41 |
| Losartan Potassium | Losartan Potassium | 154 | 34 |
| Metformin Hcl | Metformin Hcl | 147 | 36 |
| Alprazolam | Alprazolam | 132 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 29 |
| Potassium Chloride | Potassium Chloride | 121 | 31 |
| Mounjaro | Tirzepatide | 115 | 25 |
| Famotidine | Famotidine | 112 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 103 | 36 |
| Clonazepam | Clonazepam | 96 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 19 |
| Celecoxib | Celecoxib | 91 | 26 |
| Lorazepam | Lorazepam | 86 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 20 |
| Sertraline Hcl | Sertraline Hcl | 78 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 16 |
| Allopurinol | Allopurinol | 72 | 15 |
| Metformin Hcl Er | Metformin Hcl | 71 | 25 |
| Pregabalin | Pregabalin | 71 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 12 |
| Eliquis | Apixaban | 66 | 12 |
| Diazepam | Diazepam | 63 | 12 |
| Azithromycin | Azithromycin | 62 | 54 |
| Prednisone | Prednisone | 59 | 44 |
| Ezetimibe | Ezetimibe | 58 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 12 |
| Trazodone Hcl | Trazodone Hcl | 55 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 16 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 35 |
| Azelastine Hcl | Azelastine Hcl | 41 | 22 |
| Baclofen | Baclofen | 41 | suppressed |
| Ozempic | Semaglutide | 41 | 12 |
| Benazepril Hcl | Benazepril Hcl | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Cefdinir | Cefdinir | 39 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 12 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | suppressed |
| Nystatin | Nystatin | 33 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 13 |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Glipizide | Glipizide | 31 | 12 |
| Glimepiride | Glimepiride | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 15 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Mupirocin | Mupirocin | 22 | 14 |
| Temazepam | Temazepam | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | 15 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $170.41 · 8 records | Novo Nordisk Inc | Cologuard Collection Kit, JOURNAVX, Ozempic, Rybelsus, TRELEGY ELLIPTA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error